Business Wire

Winston & Strawn and Taylor Wessing UK to Combine, Creating a Premier Transatlantic Law Firm

Share

Winston & Strawn and Taylor Wessing’s UK-led business announced today their intention to combine, creating a premier transatlantic law firm that would operate under a new shared name, Winston Taylor. The combination responds to increasing client demand for seamlessly integrated US–UK–EU counsel for the businesses, people, and markets driving capital and innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215914957/en/

The combination once final will unite two international firms with more than 400 years of combined history, complementary strengths, and a common vision to meet clients’ evolving global needs. The combined firm will include more than 1,400 lawyers, establishing one of the largest transatlantic firms whose footprint is primarily in the United States, the United Kingdom, and Europe, and also in Latin America and the Middle East.

Leveraging significant strength and scale in major litigation, critical transactions, strategic IP, and private wealth, Winston Taylor will deliver best-in-class client service across key sectors including technology, life sciences, and financial services. Clients will gain a unified team with end-to-end capabilities across jurisdictions to achieve their business objectives in the breakthrough moments across their lifecycle.

“Once combined, we will have a London-headquartered partner that fulfills our long-held ambition to grow in the UK, while preserving the culture, agility, focus, and relentless client service that define Winston & Strawn,” said Steve D’Amore, Chairman of Winston & Strawn, who will continue as Chairman of the combined firm. “This combination will establish an elite practice in the major commercial centers important to our clients. Winston Taylor will be positioned to lead on the most sophisticated litigation and transactions in the world’s most defining industries.”

"In Winston & Strawn, Taylor Wessing UK will have a US partner that shares our vision, our values, and culture, and absolute focus on the highest levels of client service," said Shane Gleghorn, Managing Partner of Taylor Wessing UK, who will serve as Managing Partner of Europe and Middle East for Winston Taylor and will become a member of its Executive Committee. "By combining Winston & Strawn’s strength in the major hubs across the United States with our coverage of the key centers of London, Europe, and the Middle East we will have created a firm with the highest level of transatlantic capabilities in key practices and sectors."

Winston Taylor, once formed, will bring together two firms with aligned practices, shared clients, and cultures rooted in innovation and exceptional client service. The combined firm’s expanded corporate, private equity, real estate, finance, antitrust, regulatory, and private wealth capabilities will provide clients with end-to-end global business strategy and support. In addition, the combination of Taylor Wessing UK’s Tier 1 UK–EU holistic IP practice with Winston & Strawn’s premier U.S. intellectual property litigation practice will establish a market-leading transatlantic IP platform.

As part of the combination, Taylor Wessing the Netherlands and Belgium will enter into an agreement with Winston Taylor to operate under the Winston Taylor brand.

Completion of the combination is expected in May 2026, subject to approvals and a vote of the partners in each firm. Until then, they will operate as separate firms in the normal course. Upon closing, Taylor Wessing UK and Taylor Wessing the Netherlands and Belgium would depart the Taylor Wessing verein and Winston Taylor would seek to have a cooperation and referral relationship with the Taylor Wessing verein to provide continuity of support to clients.

Notes to editors

The combined business will have 20 offices in Amsterdam, Brussels, Cambridge, Charlotte, Chicago, Dallas, Dubai, Dublin, Eindhoven, Houston, Liverpool, London, Los Angeles, Miami, New York, Paris, San Francisco, São Paulo, Silicon Valley, and Washington DC.

For more information, visit www.winstontaylor.com.

AboutWinston & Strawn
Founded in 1853, Winston & Strawn is an Am Law 50 firm with ~1,000 lawyers across 14 offices worldwide. The firm is recognized for its leadership in litigation, intellectual property, corporate and finance transactions, and regulatory work across major sectors, including technology, life sciences, and financial services.

About Taylor Wessing UK
Founded in 1782, Taylor Wessing UK is a Top 20 UK law firm with over 450 lawyers in the UK, Ireland and the Middle East. The firm is renowned for its Tier 1 intellectual property, life sciences, technology, and private wealth practices, advising clients ranging from global corporations to leading innovators and investors.

About Taylor Wessing the Netherlands and Belgium
Taylor Wessing the Netherlands and Belgium brings together its Amsterdam, Eindhoven, and Brussels offices into a fully integrated Benelux practice, with over 100 lawyers and civil-law notaries advising high-growth technology and life sciences companies, multinational corporates, and investors on corporate transactions, intellectual property, disputes, and regulatory matters.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251215914957/en/

Contacts

WinstonTaylor@infiniteglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye